HRs between cytogenetic abnormalities and OS stratified by EAs and AAs with MM
| . | Age-adjusted HR∗ (95% CI) . | Fully adjusted HR† (95% CI) . | ||||||
|---|---|---|---|---|---|---|---|---|
| EA | AA | EA | AA | |||||
| n | n | n | n | |||||
| IMWG HRCAs‡ | 126 | 2.3 (1.1-4.5) | 53 | 0.6 (0.1-2.7) | 120 | 2.6 (1.3-5.5) | 46 | 0.6 (0.1-2.9) |
| t(4;14)(p16;q32) | 103 | 2.1 (0.8-5.4) | 44 | 10.7 (1.9-60.7) | 99 | 1.6 (0.5-4.7) | 38 | 14.5 (2.3-92.3) |
| t(11;14)(q13;q32) | 29 | 0.4 (0.1-3.4) | 10 | 1.6 (0.2-14.0) | 28 | 0.5 (0.0-6.7) | 9 | 1.8 (0.2-14.2) |
| Loss of IGH | 68 | 0.6 (0.2-1.7) | 26 | 1.3 (0.3-5.7) | 65 | 0.6 (0.2-1.9) | 22 | 4.4 (0.7-29.2) |
| IGH rearrangement | 82 | 1.4 (0.6-3.4) | 30 | 1.6 (0.5-5.2) | 80 | 1.4 (0.6-3.3) | 24 | 0.6 (0.1-2.8) |
| Trisomy of chromosome 3 | 75 | 0.5 (0.1-1.7) | 33 | 1.6 (0.4-6.2) | 71 | 0.7 (0.2-2.5) | 29 | 2.1 (0.4-11.9) |
| Trisomy of chromosome 7 | 60 | 1.8 (0.5-6.6) | 20 | 2.0 (0.4-11.0) | 57 | 1.8 (0.5-6.8) | 18 | 3.7 (0.3-46.4) |
| Trisomy of chromosome 9 | 81 | 0.9 (0.4-2.3) | 34 | 1.3 (0.4-4.2) | 77 | 1.4 (0.5-3.5) | 30 | 1.0 (0.2-5.4) |
| Chromosome 13q deletion (del 13p) | 120 | 1.5 (0.8-2.9) | 52 | 2.3 (0.9-6.0) | 114 | 2.0 (1.0-4.2) | 45 | 3.3 (1.0-2.6) |
| Gain of ATM | 75 | 0.8 (0.4-1.8) | 20 | 1.5 (0.3-8.5) | 72 | 0.8 (0.4-1.9) | 15 | — |
| Loss of TP53 [17p13.1] (del 17p) | 122 | 1.0 (0.4-2.5) | 48 | 0.5 (0.1-3.4) | 117 | 1.4 (0.5-3.7) | 42 | 0.5 (0.1-4.0) |
| Gain of TP53 | 70 | 0.6 (0.1-2.7) | 24 | 7.3 (1.5-36.9) | 68 | 0.8 (0.2-3.5) | 22 | — |
| Gain/amplification of CKS1B [1q21](+1q) | 82 | 2.8 (1.1-6.7) | 36 | 1.5 (0.4-5.9) | 77 | 3.4 (1.3-9.3) | 32 | 1.4 (0.3-6.2) |
| Tetraploidy | 22 | 0.4 (0.1-2.4) | 10 | 1.7 (0.2-15.5) | 21 | 0.4 (0.0-3.7) | 7 | — |
| . | Age-adjusted HR∗ (95% CI) . | Fully adjusted HR† (95% CI) . | ||||||
|---|---|---|---|---|---|---|---|---|
| EA | AA | EA | AA | |||||
| n | n | n | n | |||||
| IMWG HRCAs‡ | 126 | 2.3 (1.1-4.5) | 53 | 0.6 (0.1-2.7) | 120 | 2.6 (1.3-5.5) | 46 | 0.6 (0.1-2.9) |
| t(4;14)(p16;q32) | 103 | 2.1 (0.8-5.4) | 44 | 10.7 (1.9-60.7) | 99 | 1.6 (0.5-4.7) | 38 | 14.5 (2.3-92.3) |
| t(11;14)(q13;q32) | 29 | 0.4 (0.1-3.4) | 10 | 1.6 (0.2-14.0) | 28 | 0.5 (0.0-6.7) | 9 | 1.8 (0.2-14.2) |
| Loss of IGH | 68 | 0.6 (0.2-1.7) | 26 | 1.3 (0.3-5.7) | 65 | 0.6 (0.2-1.9) | 22 | 4.4 (0.7-29.2) |
| IGH rearrangement | 82 | 1.4 (0.6-3.4) | 30 | 1.6 (0.5-5.2) | 80 | 1.4 (0.6-3.3) | 24 | 0.6 (0.1-2.8) |
| Trisomy of chromosome 3 | 75 | 0.5 (0.1-1.7) | 33 | 1.6 (0.4-6.2) | 71 | 0.7 (0.2-2.5) | 29 | 2.1 (0.4-11.9) |
| Trisomy of chromosome 7 | 60 | 1.8 (0.5-6.6) | 20 | 2.0 (0.4-11.0) | 57 | 1.8 (0.5-6.8) | 18 | 3.7 (0.3-46.4) |
| Trisomy of chromosome 9 | 81 | 0.9 (0.4-2.3) | 34 | 1.3 (0.4-4.2) | 77 | 1.4 (0.5-3.5) | 30 | 1.0 (0.2-5.4) |
| Chromosome 13q deletion (del 13p) | 120 | 1.5 (0.8-2.9) | 52 | 2.3 (0.9-6.0) | 114 | 2.0 (1.0-4.2) | 45 | 3.3 (1.0-2.6) |
| Gain of ATM | 75 | 0.8 (0.4-1.8) | 20 | 1.5 (0.3-8.5) | 72 | 0.8 (0.4-1.9) | 15 | — |
| Loss of TP53 [17p13.1] (del 17p) | 122 | 1.0 (0.4-2.5) | 48 | 0.5 (0.1-3.4) | 117 | 1.4 (0.5-3.7) | 42 | 0.5 (0.1-4.0) |
| Gain of TP53 | 70 | 0.6 (0.1-2.7) | 24 | 7.3 (1.5-36.9) | 68 | 0.8 (0.2-3.5) | 22 | — |
| Gain/amplification of CKS1B [1q21](+1q) | 82 | 2.8 (1.1-6.7) | 36 | 1.5 (0.4-5.9) | 77 | 3.4 (1.3-9.3) | 32 | 1.4 (0.3-6.2) |
| Tetraploidy | 22 | 0.4 (0.1-2.4) | 10 | 1.7 (0.2-15.5) | 21 | 0.4 (0.0-3.7) | 7 | — |
LDH, elevated lactate dehydrogenase levels.
HRs were calculated using the Cox proportional hazards regression models adjusting for age (years).
In EAs, the Cox model included age (years), sex (female/male), ISS (1/2-3), LDH (normal/elevated). In AAs, the Cox model included age (years), sex (female/male), and (ISS) (1/2-3).
IMWG molecular classification of MM: High-risk MM was defined by the presence of any HRCAs, including t(4;14), t(14;16), t(14;20), del 17p, and gain/amplification of 1q 19. Standard-risk MM was defined by the absence of HRCAs or the presence of any trisomies of odd-numbered chromosomes or t(11;14).